Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG

Publication date: Available online 7 September 2018Source: BiologicalsAuthor(s): Sjoerd Rijpkema, Jason Hockley, Alastair Logan, Peter Rigsby, Eleanor Atkinson, Celina Jin, David Goldblatt, Haoyu Liang, Novilia S. Bachtiar, Jae Seung Yang, Akshay Goel, Venkatesan Ramasamy, Marcela F. Pasetti, Andrew J. Pollard, the anti-Vi IgG working groupAbstractVi capsular polysaccharide (Vi) conjugate vaccines, which can prevent typhoid in infants and young children, are being developed. Comparative immunogenicity studies are facilitated by an International Standard (IS) for human anti-Vi IgG. 16/138, a pool of sera from volunteers which received either Vi conjugate vaccine or plain Vi vaccine, was assessed as an IS alongside U.S. reference reagent Vi-IgGR1, 2011. Samples were tested in a commercial ELISA (n = 7), a standardised ELISA based on biotinylated Vi (n = 7) and in-house ELISAs (n = 7). Valid estimates were obtained for the potency of all samples in the commercial ELISA, and the commutability of 16/138 and Vi-IgGR1, 2011 was evident for the commercial ELISA and in-house ELISAs based on a coating of Vi and protein. The WHO Expert Committee on Biological Standardization established 16/138 as the first IS for anti-Vi IgG with 100 IU per ampoule and assigned 163 IU per vial of Vi-IgGR1, 2011.
Source: Biologicals - Category: Biology Source Type: research